Filing Details
- Accession Number:
- 0000904454-14-000809
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-18 10:43:17
- Reporting Period:
- 2014-12-16
- Filing Date:
- 2014-12-18
- Accepted Time:
- 2014-12-18 10:43:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1404644 | Aquinox Pharmaceuticals Inc | AQXP | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 200406 | Johnson & Johnson | One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933 | No | No | Yes | No | |
| 924020 | Johnson & Johnson Development Corp Et Al | One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-12-16 | 6,507 | $7.63 | 1,343,687 | No | 4 | S | Indirect | Johnson & Johnson Development Corporation |
| Common Stock | Disposition | 2014-12-17 | 1,593 | $7.58 | 1,342,094 | No | 4 | S | Indirect | Johnson & Johnson Development Corporation |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | Johnson & Johnson Development Corporation |
| No | 4 | S | Indirect | Johnson & Johnson Development Corporation |
Footnotes
- The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.60 to $7.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $7.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Billionaire Hedge Funds
